2017 DTRF Desmoid Tumor Research Workshop  
Sunday, September 24, 2017  
(Tentative agenda as of 8.10.17)

7:15-8:00 Continental breakfast and informal introductions.

8:00-8:05 Welcome: Jeanne Whiting, President & Co-Founder, DTRF.

8:05-8:20 David Kirsch, MD, PhD, Barbara Levine University Professor and Vice Chair for Basic & Translational Research, Department of Radiation Oncology Professor, Department of Pharmacology & Cancer Biology, Duke University, “Using radiation therapy to treat desmoid tumors.”

8:20-8:35 Tom van Cann, MD, Medical oncologist, KU Leuven, “Systemic treatment preferences for patients with advanced desmoid-type fibromatosis in Europe.”

8:35-8:50 Yuhong Zhou, MD, PhD, Professor & Oncologist, Zhongshan Hospital, Fudan University, “The treatments and clinical outcomes of sporadic and fap-associated desmoid tumor: a single centre long-term observational study.”

8:50-9:05 Milea J.M. Timbergen, MD, PhD candidate, Erasmus Medical Center, “Results of the interim analysis of the Dutch GRAFITI study.”

8:05-9:20 Breelyn Wilky, MD, Assistant Professor in Hematology/Oncology, University of Miami Sylvester Comprehensive Cancer Center, “Mutation phenotypes and their responses to chemotherapy.”

9:20-9:35 Discussion


9:50-10:05 Yoshihiro Nishida, MD, PhD, Associate Professor, Nagoya University Graduate School of Medicine, “Effects of mechanical forces on the cell behavior of desmoid-type fibromatosis.”

10:05-10:20 Danielle Braggio, PhD, Post-Doctoral Researcher, Ohio State University, “Autophagy inhibition overcomes sorafenib resistance in S45F-mutated desmoid tumors.”

10:20-10:35 Kris Vleminckx, PhD, Professor, Department of Molecular Biomedical Research Unit of Developmental Biology VIB, Ghent University, “Therapeutic target identification in a Xenopus model for desmoid tumor formation – an update.”

10:35-10:50 Gerlinde Wernig, MD, Assistant Professor of Pathology, Stanford University, “Unifying mechanism on different fibrotic diseases.”

10:50-11:05 Discussion

11:05-11:40 TBD

11:40-11:45 Steve Horrigan, PhD, Chief Scientific Officer, Beta Cat Pharmaceuticals, “Tegavivint (BC2059) – A new way of attacking beta catenin driven disease.”

11:45-11:55 Danielle Braggio, PhD, Post-Doctoral Researcher in Sarcomas, Ohio State University, “Tegavivint (BC2059) studies in desmoid cell lines.”
11:55-12:05  **Benjamin Alman, MD**, Professor and Chair, Department of Orthopaedic Surgery, Duke University, “Tegavivint (BC2059) studies in Apc(+)/Apc(1638N) genetic mouse model of aggressive fibromatosis.”

12:05-12:15  **Casey Cunningham, MD**, Chief Medical Officer, Beta Cat Pharmaceuticals, “Synopsis of a Planned Phase 1/2 Study of Tegavivant (BC2059) in Desmoid Tumors.”

12:15-12:45  Lunch break - continue discussion

12:45-1:45  Lunch

1:45-2:10  **Benjamin Alman, MD**, Department Chair, Orthopedic Surgery, Duke University, “Introduction and report on Collaboration for a Cure project.”


2:50-4:00  SUMMARY DISCUSSION and SETTING OF PRIORITIES